Prestige Biologics프레스티지바이오로직스
334970 · KOSDAQ · ₩334970 · 프레스티지바이오로직스
- Market cap
- ₩96B
- Enterprise value
- ₩186B
- P/E
- —
- P/B
- 0.7×
- Dividend yield
- 0.0%
- ROE
- −20.3%
- Net margin
- −219.2%
Trailing 12 months from filed financial statements, as of FY 2025. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−68.0% from the high
₩1,200Today: ₩1,200 – ₩1,280₩3,850
Returns
- 1W−6.4%
- 1M−9.8%
- 3M−31.5%
- 6M−48.5%
- YTD−59.4%
- 1Y−60.5%
- Volume today
- 84,866
- 1.0× the 20-day average
- Traded today
- ₩103M
- Listed shares
- 77,752,637
- EPS (12 months)
- −₩353
- Earnings yield −28.7%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 42 of 100 (50 is a normal day for this stock).
- MomentumWeak-10.5% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Prestige Biologics stock overview
Prestige Biologics (프레스티지바이오로직스, KRX: 334970) is listed on KOSDAQ, in the Biotech & Pharma sector. Prestige Biologics is a Korean contract development and manufacturing organization (CDMO) for biopharmaceuticals, offering process development, clinical and commercial drug substance and drug product manufacturing including fill-finish, contract packaging, and contract testing and analytical services. Its shares closed at ₩1,231 on Oct 27, 2026, down 1.68% on the day, giving it a market value of ₩96B.
Key facts
- Market cap
- ₩96B
- Sector
- Biotech & Pharma
- Latest price change
- −1.68%
- As of
- Oct 27, 2026
- Main business
- Prestige Biologics is a Korean contract development and manufacturing organization (CDMO) for biopharmaceuticals, offering process development, clinical and commercial drug substance and drug product manufacturing including fill-finish, contract packaging, and contract testing and analytical services.
Quick answers about Prestige Biologics
- What does Prestige Biologics do?
- Prestige Biologics is a Korean contract development and manufacturing organization (CDMO) for biopharmaceuticals, offering process development, clinical and commercial drug substance and drug product manufacturing including fill-finish, contract packaging, and contract testing and analytical services. Its services are offered modularly or as an integrated one-stop CDMO model covering development through commercial production and packaging, serving pharmaceutical and biotech companies. The company operates production campuses in Korea with a stated total capacity of 154,000 liters and holds regulatory certifications including Korea MFDS GMP, EU GMP, WHO GDP, and Brazil ANVISA GMP.
- What is the market cap of Prestige Biologics?
- The market capitalisation of Prestige Biologics was ₩96B at the close on Oct 27, 2026.
- Who are the largest shareholders of Prestige Biologics?
- According to the latest official filings, the largest reported holders are Prestige Biopharma (60.37%, as of Jul 10, 2026); Kim Michael Jinwoo (10.05%, as of Jul 10, 2026); Dong Hyeon-cheol (0.15%, as of Jun 4, 2025).
- When is the next earnings report from Prestige Biologics?
- Korean companies rarely announce results dates in advance. Based on when Prestige Biologics filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
Prestige Biologics is a Korean contract development and manufacturing organization (CDMO) for biopharmaceuticals, offering process development, clinical and commercial drug substance and drug product manufacturing including fill-finish, contract packaging, and contract testing and analytical services. Its services are offered modularly or as an integrated one-stop CDMO model covering development through commercial production and packaging, serving pharmaceutical and biotech companies. The company operates production campuses in Korea with a stated total capacity of 154,000 liters and holds regulatory certifications including Korea MFDS GMP, EU GMP, WHO GDP, and Brazil ANVISA GMP.
Written by AI from the company's latest annual report.
- Korean name
- 프레스티지바이오로직스
- Sector
- Biotech & Pharma
- Themes
- Biosimilars
- CEO
- 김진우
- Founded
- Jun 2015
- Listed
- Mar 2021
- Listed shares
- 77,752,637
- Fiscal year ends
- Month 06
- Website
- www.prestigebiologics.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- [Amended Filing] Share Consolidation Decision (Withdrawn)Sep 30, 2026
- Other Material Management Matters (Withdrawal of Share Consolidation Decision)Sep 30, 2026
- Annual general meeting resultsSep 30, 2026
- Amended: Annual report (Jun 2026)Sep 28, 2026
- Amended: Major sales or supply contractSep 21, 2026
Titles in Korean until English translations are added.
Also known as: Prestige Biologics / 프레스티지바이오로직스 / 334970 / KRX:334970
Source: KRX statistical information